Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty (HOVIGAMI-ESG)
Roles of Hormonal Modulation and the Microbiota in Gastric Emptying and Metabolic Response After Endoscopic Sleeve Gastroplasty
Obesity is a chronic disease with a rapidly increasing prevalence, expected to affect up to 25% of the French population by 2030, and is associated with significant morbidity, mortality, and healthcare burden. Bariatric surgery, including sleeve gastrectomy and gastric bypass, remains the standard treatment for severe obesity but is irreversible and carries procedural risks.
Less invasive alternatives have emerged, including pharmacological treatments (GLP-1 receptor agonists and multi-agonists) and endoscopic approaches such as endoscopic sleeve gastroplasty (ESG), which have shown efficacy in weight loss and metabolic improvement, although drug therapies are limited by weight regain after discontinuation.
Sleeve gastrectomy, the most frequently performed bariatric procedure in France, induces weight loss through gastric restriction and hormonal changes, including decreased ghrelin and increased GLP-1 and PYY, along with accelerated gastric emptying.
ESG is a minimally invasive endoscopic technique with mechanisms that remain incompletely understood, likely involving gastric restriction, altered gastric emptying, and hormonal and microbiome-related effects.
Bariatric outcomes are driven by complex interactions between gastric anatomy, motility, hormonal regulation, and the gut microbiome. An integrated evaluation of these parameters is needed to better understand response variability after intervention.
A total of 40 patients will be enrolled (20 per group).
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Obesity is a chronic disease with increasing prevalence, projected to affect up to 25% of the French population by 2030, and is associated with significant morbidity, mortality, and healthcare burden. Bariatric surgery, including sleeve gastrectomy and gastric bypass, remains the reference treatment for severe obesity but is irreversible and associated with procedural risks.
Less invasive alternatives have emerged, including pharmacological treatments (GLP-1 receptor agonists and multi-agonists) and endoscopic procedures such as endoscopic sleeve gastroplasty (ESG). These approaches have demonstrated efficacy in weight loss and metabolic improvement, although pharmacological treatments are limited by weight regain after discontinuation and reduced long-term adherence.
Sleeve gastrectomy, the most commonly performed bariatric procedure in France, induces weight loss through gastric restriction, hormonal changes (including reduced ghrelin and increased GLP-1 and PYY), and accelerated gastric emptying. In contrast, ESG is a minimally invasive endoscopic technique with mechanisms that remain incompletely understood, with emerging data suggesting delayed gastric emptying.
Beyond mechanical restriction, the metabolic effects of bariatric interventions involve complex interactions between gastric anatomy, motility, gut hormones, and the microbiome. Gastric emptying, a key determinant of satiety and hormonal response, differs between procedures and may contribute to variability in weight loss outcomes. Hormonal adaptations and microbiome changes after ESG remain insufficiently characterized.
This study adopts an integrative approach combining gastric volumetry, gastric emptying assessment, hormonal profiling, and microbiome analysis to better understand mechanisms of response and inter-individual variability after bariatric interventions.
A total of 40 patients will be enrolled (20 per group), with treatment allocation determined by a multidisciplinary team. Participants will undergo serial assessments including blood sampling, standardized meal test hormone measurements, CT-based gastric volumetry, and gastric emptying scintigraphy. Endoscopic biopsies will be performed at 12 months in the ESG group, while gastroscopy in the surgical group will be performed only if clinically indicated.
The study aims to improve mechanistic understanding of bariatric interventions, identify predictors of response, and support personalized therapeutic strategies in obesity management.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Maxime AMOYEL, DM
- Telefonnummer: 01 40 25 76 52
- E-post: Maxime.amoyal@aphp.fr
Studiesteder
-
-
Paris
-
Paris, Paris, Frankrike, 75018
- Bichat Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Male or female, age ≥ 18 years
- BMI between 30 and 40 kg/m²
- With or without obesity-related comorbidities (hypertension, diabetes, -obstructive sleep apnea, etc.)
- Indication for ESG (Endoscopic Sleeve Gastroplasty) or surgical sleeve gastrectomy validated in a multidisciplinary team meeting
- Patient with an indication to undergo CT scan and scintigraphy
- Written informed consent
- Affiliation with a health insurance system
Exclusion Criteria:
- Patient receiving anti-obesity treatment (GLP-1 analogs, multi-agonists)
- History of prior gastric surgery
- History of gastric or distal esophageal cancer
- History of gastric dysplasia
- Presence of a hiatal hernia > 2 cm
Contraindication to general anesthesia, including:
- Severe coagulation disorders, including uncontrolled congenital or acquired hemostasis disorders, severe thrombocytopenia (platelets < 50 G/L), non-interruptible anticoagulant or antiplatelet therapy according to current guidelines, uncorrected INR > 1.5
- Hemodynamic instability, defined as persistent hypotension or shock, uncontrolled cardiac arrhythmias, or need for vasopressor support
- Decompensated cardiac disease, including uncontrolled heart failure (NYHA III-IV), unstable ischemic heart disease or recent acute coronary syndrome, untreated severe valvular disease, uncontrolled severe hypertension
- Decompensated respiratory disease, including acute or severe chronic respiratory failure not stabilized, uncontrolled severe COPD, untreated severe obstructive sleep apnea, persistent hypoxemia requiring high-flow oxygen therapy
- Any other clinical condition considered incompatible with general anesthesia or endoscopy by the anesthesiologist or investigator, according to current guidelines and patient safety considerations Significant or unstable renal insufficiency, or history of severe reaction to iodinated contrast agents
- Participation in another clinical research study, except for non-interventional studies
- Patient under legal protection (guardianship, curatorship, or judicial protection)
- Physical inability to provide written informed consent
- Rare forms of obesity of genetic and/or central origin (e.g., associated with craniopharyngioma)
- Pregnancy or breastfeeding
- State medical aid (AME)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Laparoscopic sleeve gastrectomy
Intervention assigned during a multidisciplinary team meeting (MDT).
|
Participants undergo laparoscopic sleeve gastrectomy with 12-month follow-up including clinical, metabolic, imaging, hormonal and microbiota assessments.
|
|
Annen: Endoscopic sleeve gastroplasty
Intervention assigned during a multidisciplinary team meeting (MDT).
|
Participants undergo endoscopic sleeve gastrectomy with 12-month follow-up including clinical, metabolic, imaging, hormonal and microbiota assessments.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gastric emptying evolution after endoscopic sleeve gastroplasty versus surgical sleeve
Tidsramme: Baseline to 12 months post-intervention
|
Assessment of gastric emptying using scintigraphic measurement to compare physiological changes induced by endoscopic sleeve gastroplasty versus surgical sleeve.
|
Baseline to 12 months post-intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gastric microbiota diversity assessed by 16S rRNA sequencing
Tidsramme: Baseline to 12 months
|
Gastric microbiota diversity assessed from gastric biopsies using 16S rRNA gene sequencing and expressed using the Shannon diversity index.
|
Baseline to 12 months
|
|
Total Body Weight Loss (TBWL)
Tidsramme: Baseline, 1, 3, 6 and 12 months
|
Total Body Weight Loss expressed as percentage (%) of initial body weight.
|
Baseline, 1, 3, 6 and 12 months
|
|
Postprandial GLP-1 plasma concentration after standardized meal test
Tidsramme: Baseline, 1, 3, 6 and 12 months
|
GLP-1 plasma concentrations measured at T0, T30, T90 and T180 following a standardized meal test.
Results expressed in pmol/L.
|
Baseline, 1, 3, 6 and 12 months
|
|
Correlation between gastric emptying and GLP-1 plasma levels
Tidsramme: Baseline to 12 months
|
Correlation between gastric emptying assessed by scintigraphy (gastric half-emptying time in minutes) and GLP-1 plasma concentrations measured after a standardized meal test.
|
Baseline to 12 months
|
|
Correlation between gastric emptying and PYY plasma levels
Tidsramme: Baseline to 12 months
|
Correlation between gastric emptying assessed by scintigraphy (gastric half-emptying time in minutes) and PYY plasma concentrations measured after a standardized meal test.
|
Baseline to 12 months
|
|
Correlation between gastric emptying and GIP plasma levels
Tidsramme: Baseline to 12 months
|
Correlation between gastric emptying assessed by scintigraphy (gastric half-emptying time in minutes) and GIP plasma concentrations measured after a standardized meal test.
|
Baseline to 12 months
|
|
Correlation between gastric emptying and ghrelin plasma levels
Tidsramme: Baseline to 12 months
|
Correlation between gastric emptying assessed by scintigraphy (gastric half-emptying time in minutes) and ghrelin plasma concentrations measured after a standardized meal test
|
Baseline to 12 months
|
|
Gastric volume assessed by CT-based volumetry
Tidsramme: Baseline, 1 month and 12 months
|
Measurement of gastric volume using CT scan (gastroscanner) with volumetric reconstruction.
Results expressed in milliliters (mL).
|
Baseline, 1 month and 12 months
|
|
Effect of gastric emptying time on total body weight loss
Tidsramme: Baseline to 12 months
|
Total body weight loss (%), analyzed according to gastric half-emptying time (minutes) assessed by gastric scintigraphy using linear regression.
|
Baseline to 12 months
|
|
Effect of postprandial GLP-1 plasma concentration on total body weight loss
Tidsramme: Baseline to 12 months
|
Total body weight loss (%), analyzed according to plasma GLP-1 concentration (pmol/L) measured after a standardized meal test using biochemical assay and linear regression.
|
Baseline to 12 months
|
|
Effect of gastric volume on total body weight loss
Tidsramme: Baseline to 12 months
|
Total body weight loss (%), analyzed according to gastric volume (mL) measured by computed tomography (CT scan) using linear regression.
|
Baseline to 12 months
|
|
Effect of gastric microbiota diversity on total body weight loss
Tidsramme: Baseline to 12 months
|
Total body weight loss (%), analyzed according to gastric microbiota diversity assessed using the Shannon diversity index derived from 16S rRNA gene sequencing using linear regression.
|
Baseline to 12 months
|
|
Safety and tolerability of endosleeve versus surgical sleeve
Tidsramme: From intervention to 12 months
|
Incidence of adverse events including digestive, hemorrhagic, infectious, anesthetic and nutritional complications, rehospitalization and mortality.
|
From intervention to 12 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- APHP251929
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .